Substituted Oxazole Carboxamide Derivatives for VR1 Receptor Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain treatments, particularly for neuropathic pain, lack effective compounds with optimal affinity to vanilloid receptor 1 (VR1/TRPV1), metabolic stability, solubility, and bioavailability, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of substituted oxazole and thiazole-based carboxamide and urea derivatives that exhibit high affinity to VR1/TRPV1 receptors, improved metabolic stability, solubility, and reduced interactions with transporter molecules, enhancing oral bioavailability and pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pain treatment compounds are used, then they can address neuropathic pain, but they lack optimal affinity to vanilloid receptor 1 and insufficient metabolic stability
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structure parameters of the compounds. Specifically, it introduces substituted oxazole and thiazole rings with various substituents (halogens, alkyl groups, alkoxy groups) at specific positions, and adjusts the carboxamide/urea linkage parameters to optimize both VR1 receptor affinity and metabolic stability simultaneously
Solution Approach 2:
The patent employs composite material principles by creating complex molecular structures that combine multiple functional moieties: the oxazole or thiazole heterocyclic core, substituted aromatic rings, and carboxamide or urea linkages. This composite structure approach allows the molecule to achieve both high receptor affinity through specific interactions and improved metabolic stability through strategic placement of metabolically resistant groups
2Reliability
If current pain treatment compounds are used, then they can provide analgesic effect, but they have poor solubility and low oral bioavailability
Solution Approach 1:
The patent applies local quality principles by introducing specific substituents at strategic positions on the molecular structure to improve solubility without compromising analgesic activity. Hydrophilic groups such as hydroxyl, alkoxy, and carboxylic acid groups are placed at specific locations on the aromatic rings and heterocyclic systems to enhance aqueous solubility, while the core VR1-binding moieties are preserved to maintain analgesic effect
Solution Approach 2:
The patent modifies physicochemical parameters of the compounds including molecular weight, logP (lipophilicity), and hydrogen bonding capacity by selecting appropriate substituents. These parameter changes optimize the balance between membrane permeability and solubility, thereby improving oral bioavailability while maintaining the analgesic effect through preserved VR1 receptor affinity
3Reliability
If current pain treatment compounds are used, then they can treat pain disorders, but they show strong interactions with transporter molecules and decomposition enzymes
Solution Approach 1:
The patent applies the taking out principle by removing or minimizing structural features that promote unwanted interactions with transporter molecules and decomposition enzymes. The molecular design avoids common pharmacophores that are substrates for P-glycoprotein and other efflux transporters, and eliminates labile functional groups that are prone to enzymatic degradation, thereby reducing harmful interactions while preserving the core VR1-binding structure necessary for pain treatment efficacy
Data Source
AI summary
The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.